Developing innovative wound care technology, with marine ingredients from the coast of Norway

Regenics AS is a private Norwegian biotechnology company based in Oslo. The company develops a range of wound care products, with a current pipeline of two medical devices and one novel drug.

Target diagnoses and applications include burns, diabetic wounds, chronic wounds, and enzymatic wound debridement. One of our major innovations, HTX™, is a bioactive substance sourced and purified from unfertilized salmon roe.
We are committed to greatly improving treatment outcomes in advanced wound management. Combining the unique healing properties of salmon roe with other marine ingredients, our products aim to redefine current standards of care.
ABOUT REGENICS
Collex® is a unique, 3D printed, advanced wound dressing containing HTX™ from salmon roe. Collex® is intended to aid healing of partial thickness burns and chronic wounds, and is currently in pre-clinical development.
Vernex® is an HTX™-based hydrogel wound spray, intended for treatment of partial thickness burns and chronic wounds. Vernex® is currently in pre-clinical development.
WoundClear™ is a novel investigational drug derived from trout LCE, intended for enzymatic wound debridement. WoundClear™ is currently in the discovery stage.
Our products
Pipeline
REG212
Wound healing
HTX from salmon roe• Advanced wound dressing• Medical device class III
Feasibility
Pre-Clinical
Pivotal
Discovery
REG320
Wound healing
HTX from salmon roe • Hydrogel wound spray• Medical device class III
Feasibility
Pre-Clinical
Pivotal
Discovery
REG410
Wound healing
LCE from trout • Enzymatic debridement• Novel drug
Phase 1
Discovery
Phase 2
Phase 3
Pre-Clinical
News
Team
Management
Karl Rasmus Bryn
Chief Executive Officer
Karin Gilljam
Chief Scientific Officer
Board
Jan Alfheim
Chairman of the Board
Runhild Gammelsæter
Board Member
Tore Heldrup Rasmussen
Board member
Harald Nordal
Board Member
Team
Chief Executive Officer
Karl Rasmus Bryn
Karl R. Bryn is the Chief Executive Officer of Regenics AS. Karl is an MD from NTNU, Trondheim, and came to Regenics from the role of Director of Digital & Business Development at Aleris Helse.

Previously, Karl served as a consultant for McKinsey & Company, working with growth and portfolio strategy across industries.

Karl also has several years of clinical experience as a medical doctor.
Chief Scientific Officer
Karin Gilljam
Karin Gilljam is the Chief Scientific Officer of Regenics AS. Karin has a PhD from the University of Oslo, and came to Regenics from a Postdoc position at the UiO Department of Molecular Medicine.

Karin has an extensive academic background in biochemistry, molecular medicine, immunology and oncology. Previously she has held a Postdoc position at NTNU Trondheim, Department of Cancer Research and Molecular Medicine.

Karin is responsible for overall scientific oversight and quality at Regenics, and coordinates the Horizon 2020 AquaHeal 3D EU commision project.